SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cancer - Side effect drugs
An SI Board Since May 2002
Posts SubjectMarks Bans
57 4 0
Emcee:  John McCarthy Type:  Moderated
Introduction Compact
Just Links.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
572002 - [NSC12983][Complete PDF file] www3.oup.co.ukJohn McCarthy-11/24/2002
562002 - [NSC12983] : Anticancer Drug Des 2001 Apr-Jun;16(2-3):129-33 Related ArtJohn McCarthy-11/24/2002
55[]John McCarthy-11/24/2002
542002 - [IDN5109] Oral administration of a novel taxane, an antisense oligonucleJohn McCarthy-11/24/2002
532002 - [IDN5109] Chem Biol 2002 Jan;9(1):93-101 Related Articles, Links EfJohn McCarthy-11/24/2002
522002 - [IDN5109][Bay 59-8862] Medicinal chemistry and chemical biology of new gJohn McCarthy-11/24/2002
512002 - [IDN5109][Overcoming multidrug resistance] Overcoming multidrug resistanJohn McCarthy-11/24/2002
50[]John McCarthy-11/24/2002
49[]John McCarthy-10/29/2002
48[]John McCarthy-10/4/2002
472002 - [SB-T-1213, SB-T-1250 and SB-T-101187][novel taxanes] December 2000, VolJohn McCarthy-7/11/2002
46[]John McCarthy-7/11/2002
45[2002] [BAX GENE][BNP1350] 1: Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (ShangJohn McCarthy-6/21/2002
44[]John McCarthy-5/18/2002
43[2002]-[ONT-093]-[oral P-gp inhibitor][Biospace] Ontogen Corporation is a drug John McCarthy-5/18/2002
42[2002]-[ONT-093]-[oral P-gp inhibitor][FUTURE ONCOLOGY] All in all, this issue John McCarthy-5/18/2002
41[2002]-[ONT-093]-[oral P-gp inhibitor][Ontogen Announces Formation of Oncology AJohn McCarthy-5/18/2002
40[2002]-[ONT-093]-[oral P-gp inhibitor][Ontogen] Oncology ONT-093: Reversing MJohn McCarthy-5/18/2002
39[2002]-[ONT-093]-[oral P-gp inhibitor][Phase 1] Reversing Multidrug Resistance John McCarthy-5/18/2002
38[]John McCarthy-5/18/2002
37[2000]-[XR9576]-[P-Glycoprotein Inhibitor][Phase I trial of XR9576 in healthy voJohn McCarthy-5/18/2002
36[2001]-[XR9576]-[P-Glycoprotein Inhibitor][In vitro and in vivo reversal of P-glJohn McCarthy-5/18/2002
35[2002]-[XR9576]-[P-Glycoprotein Inhibitor][Reversal of multidrug resistance: lesJohn McCarthy-5/18/2002
34[2001]-[XR9576]-[P-Glycoprotein Inhibitor][Phase 3 Trials] There will be 2 phasJohn McCarthy-5/18/2002
33[2001]-[XR9576]-[P-Glycoprotein Inhibitor][Xenova and QLT sign licence agreementJohn McCarthy-5/18/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News